(Q36719701)

15 August 2017

1 reference

title

Topotecan in the management of cervical cancer (English)

1 reference

15 August 2017

main subject

cervix uterine cancer

1 reference

2

Bradley J Monk

1 reference

15 August 2017

author name string

Leslie M Randall-Whitis

series ordinal

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

227-236

1 reference

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Factors affecting topotecan sensitivity in human leukemia samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Topotecan for recurrent cervical cancer after platinum-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase I study of topotecan and radiation therapy in advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.227

21 January 2018

Identifiers

DOI

10.1517/14656566.8.2.227

1 reference

15 August 2017

1 reference